A proposed mechanism of MNTX synergistic effects with temsirolimus on inhibition of VEGF-induced angiogenic events

Schematic diagram of a proposed mechanism of MNTX synergistic effects with temsirolimus on inhibition of VEGF-induced angiogenic events. VEGF binding to VEGF receptors (1) induces Src activation (tyrosine phosphorylation)(2), Src-mediated PI3 kinase/PDK1 activation with consequent phospho-threonine308 Akt phosphorylation (3) and mTOR Complex 2 formation (mTOR/SIN1/Rictor) with consequent phospho-serine473 Akt phosphorylation (4). Activated (serine/threonine phosphorylated) Akt promotes mTOR Complex 1 formation (mTOR/FKBP12/Raptor) (5) required for EC proliferation and migration (6). MNTX inhibits the mu opioid receptor and promotes tyrosine phosphatase activity and Src inactivation (7). Temsirolimus binds to FKBP12 and inhibits mTOR Complex 2 formation (8). Therefore, the synergistic effects of MNTX with temsirolimus are achieved through inhibition of different components of a common VEGF-induced angiogenic signaling pathway. MNTX can have important clinical utility by potentially lower the therapeutic dose of temsirolimus in the treatment of various diseases requiring angiogenesis including cancer.

Publication

Methylnaltrexone Potentiates the Anti-Angiogenic Effects of mTOR Inhibitors. (2010) Patrick A Singleton, et al. J Angiogenes Res. 2010;2:5-5. Figure: F9. All organisms Drosophila melanogaster Homo sapiens

Disease mentions